BRAF mutations are observed in approximately 10% of all patients diagnosed with CRC and lead to unique morphological, clinical, and therapeutic characteristics [53]; in addition, they were reported to be linked with the right-sided tumor localization and antiepithelial growth factor receptor (EGFR) therapy resistance [54]. The gene discussed is BRAF; the disease is colorectal carcinoma.